Andrew T Kuykendall (Andrew Kuykendall)

Scopus Author ID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 44

Top Venues

American journal of hematology

Annals of hematology

Blood cancer discovery

Blood advances

H Lee Moffitt Cancer Center and Research Institute

This page only lists publications with an associated author ORCID identifier.

Affiliation History

H Lee Moffitt Cancer Center and Research Institute

United States

Assitant Member :: Malignant Hematology

Publications

Nicole D Vincelette, Xiaoqing Yu, Andrew T Kuykendall, Jungwon Moon, Siyuan Su, Chia-Ho Cheng, Rinzine Sammut, Tiffany N Razabdouski, Hai Vu Nguyen, Erika A Eksioglu, Onyee Chan, Najla Al Ali, Parth C Patel, Dae Hyun Lee, Shima Nakanishi, Renan B Ferreira, Elizabeth Hyjek, Qianxing Mo, Suzanne Cory, Harshani R Lawrence, Ling Zhang, Daniel J Murphy, Rami S Komrokji, Daesung Lee, Scott H Kaufmann, John L Cleveland, Seongseok Yun
Trisomy 8 Defines a Distinct Subtype of Myeloproliferative Neoplasms Driven by the MYC-Alarmin Axis. Blood cancer discovery 5 (4) (2024)
Nicole D Vincelette, Xiaoqing Yu, Andrew T Kuykendall, Jungwon Moon, Siyuan Su, Chia-Ho Cheng, Rinzine Sammut, Tiffany N Razabdouski, Hai Vu Nguyen, Erika A Eksioglu, Onyee Chan, Najla Al Ali, Parth C Patel, Dae Hyun Lee, Shima Nakanishi, Renan B Ferreira, Elizabeth Hyjek, Qianxing Mo, Suzanne Cory, Harshani R Lawrence, Ling Zhang, Daniel J Murphy, Rami S Komrokji, Daesung Lee, Scott H Kaufmann, John L Cleveland, Seongseok Yun
Trisomy 8 Defines a Distinct Subtype of Myeloproliferative Neoplasms Driven by the MYC-Alarmin Axis. Blood cancer discovery 5 (4) (2024)
Garima Pandey, Lucia Mazzacurati, Tegan M Rowsell, Nathan P Horvat, Narmin E Amin, Guolin Zhang, Afua A Akuffo, Christelle M Colin-Leitzinger, Eric B Haura, Andrew T Kuykendall, Ling Zhang, Pearlie K Epling-Burnette, Gary W Reuther
SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms. American journal of hematology 99 (6) (2024)
Andrew T Kuykendall, Somedeb Ball, Barbara Mora, Qianxing Mo, Najla Al Ali, Margherita Maffioli, Giuseppe Auteri, Camilla Mazzoni, Giuseppe Alberto Maria Palumbo, Andrea Duminuco, Anna Longo, Elena Maria Elli, Francesco Passamonti, Francesca Palandri, Rami S Komrokji
Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With Ruxolitinib. JCO precision oncology 8 (2024)
Onyee Chan, Najla Al Ali, Hammad Tashkandi, Austin Ellis, Somedeb Ball, Justin Grenet, Caroline Hana, Yehuda Deutsch, Ling Zhang, Mohammad Hussaini, Jinming Song, Seongseok Yun, Chetasi Talati, Andrew T Kuykendall, Eric Padron, Alison Walker, Gail J Roboz, Pinkal Desai, David A Sallman, Kendra Sweet, Rami S Komrokji, Jeffrey Lancet
Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML. Blood advances 8 (5) (2024)
Nicole D Vincelette, Xiaoqing Yu, Andrew T Kuykendall, Jungwon Moon, Siyuan Su, Chia-Ho Cheng, Rinzine Sammut, Tiffany N Razabdouski, Hai Vu Nguyen, Erika A Eksioglu, Onyee Chan, Najla Al Ali, Parth C Patel, Dae Hyun Lee, Shima Nakanishi, Renan B Ferreira, Elizabeth Hyjek, Qianxing Mo, Suzanne Cory, Harshani R Lawrence, Ling Zhang, Daniel J Murphy, Rami S Komrokji, Daesung Lee, Scott H Kaufmann, John L Cleveland, Seongseok Yun
Trisomy 8 Defines a Distinct Subtype of Myeloproliferative Neoplasms Driven by the MYC-Alarmin Axis. Blood cancer discovery 5 (4) (2024)
Lynh Nguyen, Aditi Saha, Andrew T Kuykendall, Ling Zhang
Clinical and Therapeutic Intervention of Hypereosinophilia in the Era of Molecular Diagnosis. Cancers 16 (7) (2024)
Nicole D Vincelette, Xiaoqing Yu, Andrew T Kuykendall, Jungwon Moon, Siyuan Su, Chia-Ho Cheng, Rinzine Sammut, Tiffany N Razabdouski, Hai Vu Nguyen, Erika A Eksioglu, Onyee Chan, Najla Al Ali, Parth C Patel, Dae Hyun Lee, Shima Nakanishi, Renan B Ferreira, Elizabeth Hyjek, Qianxing Mo, Suzanne Cory, Harshani R Lawrence, Ling Zhang, Daniel J Murphy, Rami S Komrokji, Daesung Lee, Scott H Kaufmann, John L Cleveland, Seongseok Yun
Trisomy 8 Defines a Distinct Subtype of Myeloproliferative Neoplasms Driven by the MYC-Alarmin Axis. Blood cancer discovery (2024)
Garima Pandey, Lucia Mazzacurati, Tegan M Rowsell, Nathan P Horvat, Narmin E Amin, Guolin Zhang, Afua A Akuffo, Christelle M Colin-Leitzinger, Eric B Haura, Andrew T Kuykendall, Ling Zhang, Pearlie K Epling-Burnette, Gary W Reuther
SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms. American journal of hematology 99 (6) (2024)
Andrew T Kuykendall, Somedeb Ball, Barbara Mora, Qianxing Mo, Najla Al Ali, Margherita Maffioli, Giuseppe Auteri, Camilla Mazzoni, Giuseppe Alberto Maria Palumbo, Andrea Duminuco, Anna Longo, Elena Maria Elli, Francesco Passamonti, Francesca Palandri, Rami S Komrokji
Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With Ruxolitinib. JCO precision oncology 8 (2024)
Garima Pandey, Lucia Mazzacurati, Tegan M Rowsell, Nathan P Horvat, Narmin E Amin, Guolin Zhang, Afua A Akuffo, Christelle M Colin-Leitzinger, Eric B Haura, Andrew T Kuykendall, Ling Zhang, Pearlie K Epling-Burnette, Gary W Reuther
SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms. American journal of hematology 99 (6) (2024)
Garima Pandey, Lucia Mazzacurati, Tegan M Rowsell, Nathan P Horvat, Narmin E Amin, Guolin Zhang, Afua A Akuffo, Christelle M Colin-Leitzinger, Eric B Haura, Andrew T Kuykendall, Ling Zhang, Pearlie K Epling-Burnette, Gary W Reuther
SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms. American journal of hematology 99 (6) (2024)
Lynh Nguyen, Aditi Saha, Andrew T Kuykendall, Ling Zhang
Clinical and Therapeutic Intervention of Hypereosinophilia in the Era of Molecular Diagnosis. Cancers 16 (7) (2024)
Lynh Nguyen, Aditi Saha, Andrew T Kuykendall, Ling Zhang
Clinical and Therapeutic Intervention of Hypereosinophilia in the Era of Molecular Diagnosis. Cancers 16 (7) (2024)
Onyee Chan, Najla H Al Ali, Hammad Tashkandi, Austin Ellis, Somedeb Ball, Justin Grenet, Caroline Hana, Yehuda Deutsch, Ling Zhang, Mohammad O Hussaini, Jinming Song, Seongseok Yun, Chetasi Talati, Andrew T Kuykendall, Eric Padron, Alison R Walker, Gail J Roboz, Pinkal Desai, David A Sallman, Kendra L Sweet, Rami S Komrokji, Jeffrey E Lancet
Mutations Highly Specific for Secondary AML are Associated with Poor Outcomes in ELN Favorable Risk NPM1-mutated AML. Blood advances (2024)
Garima Pandey, Lucia Mazzacurati, Tegan M Rowsell, Nathan P Horvat, Narmin E Amin, Guolin Zhang, Afua A Akuffo, Christelle M Colin-Leitzinger, Eric B Haura, Andrew T Kuykendall, Ling Zhang, Pearlie K Epling-Burnette, Gary W Reuther
SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms. American journal of hematology 99 (6) (2024)
Ayalew Tefferi, Giovanni Barosi, Francesco Passamonti, Juan Carlos Carlos Hernández-Boluda, Prithviraj Bose, Konstanze Döhner, Martin Ellis, Naseema Gangat, Jacqueline S Garcia, Heinz Gisslinger, Jason Gotlib, Paola Guglielmelli, Vikas K Gupta, Claire N Harrison, Elizabeth O Hexner, Gabriela S Hobbs, Jean-Jacques Kiladjian, Steffen Koschmieder, Nicolaus M Kröger, Andrew T Kuykendall, Giuseppe Gaetano Loscocco, John O Mascarenhas, Lucia Masarova, Ruben A Mesa, Barbara Mora, Olatoyosi Odenike, Stephen T Oh, Animesh D Pardanani, Anand Ashwin Patel, Naveen Pemmaraju, Alessandro Rambaldi, Raajit K Rampal, Shireen Sirhan, Natasha Szuber, Moshe Talpaz, Pankit Vachhani, Alessandro M Vannucchi, Tiziano Barbui
Proposals for Revised International Working Group-European LeukemiaNet Criteria for Anemia Response in Myelofibrosis. Blood (2024)
Onyee Chan, Najla Al Ali, Hammad Tashkandi, Austin Ellis, Somedeb Ball, Justin Grenet, Caroline Hana, Yehuda Deutsch, Ling Zhang, Mohammad Hussaini, Jinming Song, Seongseok Yun, Chetasi Talati, Andrew T Kuykendall, Eric Padron, Alison Walker, Gail J Roboz, Pinkal Desai, David A Sallman, Kendra Sweet, Rami S Komrokji, Jeffrey Lancet
Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML. Blood advances 8 (5) (2024)
Garima Pandey, Lucia Mazzacurati, Tegan M Rowsell, Nathan P Horvat, Narmin E Amin, Guolin Zhang, Afua A Akuffo, Christelle M Colin-Leitzinger, Eric B Haura, Andrew T Kuykendall, Ling Zhang, Pearlie K Epling-Burnette, Gary W Reuther
SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms. American journal of hematology (2024)
Nicole D Vincelette, Xiaoqing Yu, Andrew T Kuykendall, Jungwon Moon, Siyuan Su, Chia-Ho Cheng, Rinzine Sammut, Tiffany N Razabdouski, Hai Vu Nguyen, Erika A Eksioglu, Onyee Chan, Najla Al Ali, Parth C Patel, Dae Hyun Lee, Shima Nakanishi, Renan B Ferreira, Elizabeth Hyjek, Qianxing Mo, Suzanne Cory, Harshani R Lawrence, Ling Zhang, Daniel J Murphy, Rami S Komrokji, Daesung Lee, Scott H Kaufmann, John L Cleveland, Seongseok Yun
Trisomy 8 Defines a Distinct Subtype of Myeloproliferative Neoplasms Driven by the MYC-Alarmin Axis. Blood cancer discovery 5 (4) (2024)
Andrew T Kuykendall, Somedeb Ball, Barbara Mora, Qianxing Mo, Najla Al Ali, Margherita Maffioli, Giuseppe Auteri, Camilla Mazzoni, Giuseppe Alberto Maria Palumbo, Andrea Duminuco, Anna Longo, Elena Maria Elli, Francesco Passamonti, Francesca Palandri, Rami S Komrokji
Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With Ruxolitinib. JCO precision oncology 8 (2024)
Nicole D Vincelette, Xiaoqing Yu, Andrew T Kuykendall, Jungwon Moon, Siyuan Su, Chia-Ho Cheng, Rinzine Sammut, Tiffany N Razabdouski, Hai Vu Nguyen, Erika A Eksioglu, Onyee Chan, Najla Al Ali, Parth C Patel, Dae Hyun Lee, Shima Nakanishi, Renan B Ferreira, Elizabeth Hyjek, Qianxing Mo, Suzanne Cory, Harshani R Lawrence, Ling Zhang, Daniel J Murphy, Rami S Komrokji, Daesung Lee, Scott H Kaufmann, John L Cleveland, Seongseok Yun
Trisomy 8 Defines a Distinct Subtype of Myeloproliferative Neoplasms Driven by the MYC-Alarmin Axis. Blood cancer discovery (2024)
Naseema Gangat, Helen Ajufo, Maymona Abdelmagid, Omer Karrar, Kristen McCullough, Talha Badar, James M Foran, Jeanne Palmer, Hassan B Alkhateeb, Abhishek A Mangaonkar, Andrew T Kuykendall, Raajit K Rampal, Ayalew Tefferi
IDH1/2 inhibitor monotherapy in blast-phase myeloproliferative neoplasms: A multicentre experience. British journal of haematology (2023)
Parth C Patel, Somedeb Ball, Akriti Gupta Jain, Chen Wang, Mohammad O Hussaini, Luis E Aguirre, Onyee Chan, Seongseok Yun, Andrew T Kuykendall, Eric Padron, Kendra L Sweet, Jeffrey E Lancet, Rami S Komrokji, David A Sallman
Drivers of deep molecular response and long-term outcomes in patients with core binding factor acute myeloid leukemia. American journal of hematology (2023)
Andrew T Kuykendall
Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices. Annals of hematology (2023)
John O Mascarenhas, Anna Rita Migliaccio, Heidi E Kosiorek, Rupali Bhave, Jeanne M Palmer, Andrew T Kuykendall, Ruben A Mesa, Raajit K Rampal, Aaron T Gerds, Abdulraheem Yacoub, Kristen Pettit, Moshe Talpaz, Rami S Komrokji, Marina Kremyanskaya, Agapito Gonzalez, Frank Fabris, Kathryn Johnson, Mikaela Dougherty, Erin M McGovern, Juan Esteban Arango Ossa, Dylan Domenico, Noushin Farnoud, Rona Singer Weinberg, Amy Kong, Vesna Najfeld, Alessandro Maria Maria Vannucchi, Francesca Arciprete, Maria Zingariello, Mario Falchi, Mohamed E Salama, Carolyn Mead-Harvey, Amylou C Dueck, Lilian Varricchio, Ronald Hoffman
A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Nathan P Horvat, Enas F Abdallah, Zhuoer Xie, Najla Al Ali, Seongseok Yun, Alison Walker, Eric Padron, David Sallman, Onyee Chan, Jeffrey Lancet, Rami Komrokji, Andrew T Kuykendall
Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbidities. Annals of hematology (2023)
Andrew T Kuykendall
Correction to: Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices. Annals of hematology (2023)
Barbara Mora, Margherita Maffioli, Elisa Rumi, Paola Guglielmelli, Marianna Caramella, Andrew T Kuykendall, Francesca Palandri, Alessandra Iurlo, Valerio De Stefano, Jean-Jacques Kiladjian, Elena M Elli, Nicola Polverelli, Jason Gotlib, Francesco Albano, Richard T Silver, Giulia Benevolo, David M Ross, Timothy Devos, Oscar Borsani, Tiziano Barbui, Matteo G Della Porta, Lorenza Bertù, Rami S Komrokji, Alessandro M Vannucchi, Francesco Passamonti
Incidence of blast phase in myelofibrosis according to anemia severity. EJHaem 4 (3) (2023)
Naseema Gangat, Andrew T Kuykendall, Najla H Al Ali, Swati Goel, Maymona Abdelmagid, Aref A Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Abhishek A Mangaonkar, Mark R Litzow, William Joseph Hogan, Mithun Vinod Shah, Mirinal S Patnaik, Animesh D Pardanani, Rami S Komrokji, Ayalew Tefferi
Black African-American patients with primary myelofibrosis: a comparative analysis of phenotype and survival. Blood advances (2023)
Andrew T Kuykendall
Correction to: Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices. Annals of hematology (2023)
Andrew T Kuykendall
Correction to: Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices. Annals of hematology (2023)
Andrew T Kuykendall
Correction to: Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices. Annals of hematology (2023)
Virginia O Volpe, Najla Al Ali, Onyee Chan, Eric Padron, David A Sallman, Andrew T Kuykendall, Kendra Sweet, Jeffrey E Lancet, Rami S Komrokji
Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy-related myelodysplastic syndromes. British journal of haematology 198 (4) (2022)
Andrew T Kuykendall, Qianxing Mo, David A Sallman, Najla Al Ali, Onyee Chan, Seongseok Yun, Kendra L Sweet, Eric Padron, Jeffrey E Lancet, Rami S Komrokji
Disease-related thrombocytopenia in myelofibrosis is defined by distinct genetic etiologies and is associated with unique prognostic correlates. Cancer 128 (19) (2022)
Somedeb Ball, Todd C Knepper, Yehuda E Deutsch, Wassim Samra, Justin M Watts, Terrence J Bradley, Onyee Chan, Mohammad Omar Hussaini, Ling Zhang, Kendra L Sweet, Andrew T Kuykendall, Chetasi Talati, Eric Padron, Rami S Komrokji, Jeffrey E Lancet, David A Sallman
Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations. Cancer 128 (21) (2022)
Somedeb Ball, Akriti G Jain, Luis E Aguirre, Najla Al Ali, Yumeng Zhang, Onyee Chan, Andrew T Kuykendall, Kendra L Sweet, Jeffrey E Lancet, David M Swoboda, Eric Padron, Rami S Komrokji, David A Sallman
Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better? American journal of hematology 97 (5) (2022)
Margherita Maffioli, Barbara Mora, Somedeb Ball, Alessandra Iurlo, Elena Maria Elli, Maria Chiara Finazzi, Nicola Polverelli, Elisa Rumi, Marianna Caramella, Maria Cristina Carraro, Mariella D'Adda, Alfredo Molteni, Cinzia Sissa, Francesca Lunghi, Alessandro Vismara, Marta Ubezio, Anna Guidetti, Sabrina Caberlon, Michela Anghilieri, Rami S Komrokji, Daniele Cattaneo, Matteo Giovanni Della Porta, Toni Giorgino, Lorenza Bertù, Marco Brociner, Andrew T Kuykendall, Francesco Passamonti
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis. Blood advances 6 (6) (2022)
Claire N Harrison, Vikas K Gupta, Aaron T Gerds, Raajit K Rampal, Srdan Verstovsek, Moshe Talpaz, Jean-Jacques Kiladjian, Ruben A Mesa, Andrew T Kuykendall, Alessandro Maria Maria Vannucchi, Francesca Palandri, Sebastian Grosicki, Timothy Devos, Eric Jourdan, Marielle J Wondergem, Haifa Kathrin Al-Ali, Veronika Buxhofer-Ausch, Alberto Álvarez-Larrán, Andrea Patriarca, Marina Kremyanskaya, Adam J Mead, Sanjay Akhani, Yuri Sheikine, Gozde Colak, John O Mascarenhas
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis. Future oncology (London, England) 18 (27) (2022)
Amber C King, Taylor M Weis, Andriy Derkach, Somedeb Ball, Manu Pandey, Michael J Mauro, Aaron D Goldberg, Maximilian Stahl, Christopher Famulare, Martin S Tallman, Eunice S Wang, Andrew T Kuykendall, Raajit K Rampal
Multicenter evaluation of efficacy and toxicity of venetoclax-based combinations in patients with accelerated and blast phase myeloproliferative neoplasms. American journal of hematology (2021)
Andrew T Kuykendall, Nathan P Horvat, Garima Pandey, Rami Komrokji, Gary W Reuther
Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis. Cancers 12 (8) (2020)
Andrew T Kuykendall, Chetasi Talati, Eric Padron, Kendra L Sweet, Jeffrey E Lancet, Alan F List, David A Sallman, Rami S Komrokji
Driver mutation-specific clinical and genomic correlates differ between primary and secondary myelofibrosis. American journal of hematology 94 (12) (2019)
Andrew T Kuykendall, Chetasi Talati, Eric Padron, Kendra L Sweet, David Sallman, Alan F List, Jeffrey E Lancet, Rami S Komrokji
Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients. American journal of hematology 94 (1) (2018)
Chetasi Talati, Ling Zhang, Ghada Shaheen, Andrew T Kuykendall, Markus Ball, Qing Zhang, Jeffrey E Lancet, Kenneth S Zuckerman, Alan F List, Rami Komrokji, Lynn Moscinski, Eric Padron
Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis. Blood 129 (13) (2017)

Andrew T Kuykendall.css-eqlu8i{font-size:small;padding-left:4px;} (Andrew Kuykendall)

Publication Activity (10 Years)

Top Topics

Top Venues

Andrew T Kuykendall (Andrew Kuykendall)